Loading stock data…
Co-Diagnostics (CODX)
$2.10-0.11 (-4.98%)
Market ClosedLast close Jul 24
Co-Diagnostics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Co-Diagnostics, Inc. in the Healthcare sector is trading at $2.10 with a market capitalization of $13M. The stock is currently near its 52-week low of $1.26, remaining 60.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 0 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 0) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $145,954↓ | $263,922↑ | $145,380↓ | $162,910↑ | $50,277 |
| Gross Profit | -$47,814↓ | $121,526↑ | $119,095↓ | $130,804↑ | $28,687 |
| Operating Income | -$9.21M↓ | -$7.66M↓ | -$7.01M↑ | -$8.06M↑ | -$8.55M |
| Net Income | -$9.14M↑ | -$25.75M↓ | -$5.89M↑ | -$7.73M↓ | -$7.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-302.34%
Volume
Today's trading volume
126,246
Recent News
EXCLUSIVE: Co-Diagnostics Marks New Milestone as India TB Test Clinical Studies Begin
Co-Diagnostics Inc. (NASDAQ:CODX) on Wednesday said CoSara Diagnostics Pvt. Ltd, its joint venture in India, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro instrument. The molecular diagnostics company said the initiation of these clinical studies marks another critical milestone for the Co-Dx PCR platform, following the company’s previously announced shipment of PCR Pro instruments, mycobacterium tuberculosis (TB or MTB) test kits and proprietary sample preparati
EXCLUSIVE: Co-Diagnostics Reaches Regulatory Milestone for PCR Respiratory Test Platform
Co-Diagnostics Inc. (NASDAQ:CODX) on Wednesday said it completed clinical and analytical performance studies for the Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. Completes Studies For PCR Respiratory Test The molecular diagnostics company currently expects to include the studies in its planned submission package. The update on these studies represents a significant milestone in preparation for a Dual 510(k) and CLIA Waiver by Application submission to
Is Co-Diagnostics National Security’s Next Diagnostic Pick?
Global health emergencies are shifting sovereign biodefense strategies toward decentralized diagnostic networks capable of deploying rapid stockpiles.
Co-Diagnostics (CODX) Q4 2025 Earnings Transcript
On the line today from Co-Diagnostics, we have Dwight Egan, Chief Executive Officer; and Brian Brown, Chief Financial Officer. Earlier today, Co-Diagnostics released financial results from the fourth quarter and full year ended December 31, 2025.
Top Midday Gainers
Braiin (BRAI) said Tuesday it collaborated with Switchcraft to enable embedded utility and telecom s